Top 45 Life Science Startup Investors in Belgium in February 2025
A list of 45 angel investors and VC (Venture Capital) funds that invest in Life science startups based in Belgium. We rank investors based on the number of investments they made in Life science companies from Belgium. We update this investor list every month.Top 45 Life Science Startup Investors in Belgium in February 2025
Investor | Life Science Belgium investments |
---|---|
PMV | 6 |
Meusinvest (Noshaq) | 5 |
Qbic Fund | 4 |
Limburgse Reconversie Maatschappij | 3 |
S.R.I.W. | 3 |
Sambrinvest | 3 |
Innovation Fund | 3 |
Theodorus III | 3 |
V-Bio Ventures | 2 |
New Science Ventures | 2 |
Pierre Drion | 2 |
SFPI-FPIM | 2 |
Annie Vereecken | 2 |
VIB | 2 |
Luc Vauterin | 2 |
Fund+ | 1 |
Fonds Vives II (University of Louvain, UCL) | 1 |
Ifoghas Investments | 1 |
Innovation Industries | 1 |
BioGeneration Ventures | 1 |
Virginie Saverys | 1 |
Griet Nuytinck | 1 |
Vives Louvain Technology Fund | 1 |
6K Venture Capital | 1 |
Newton Biocapital | 1 |
Capricorn Partners | 1 |
Evren Ucok | 1 |
Epimède SA | 1 |
Qbic | 1 |
Korys | 1 |
Novo Nordisk | 1 |
European Investment Bank | 1 |
invest.bw | 1 |
Seventure Partners | 1 |
Smedvig | 1 |
Merieux Developpement | 1 |
OBI SA | 1 |
VIVES Funds | 1 |
Annemie Van de Casteele | 1 |
Kenneth Buckfire | 1 |
Opdorp Finance BVBA | 1 |
WING by Digital Wallonia | 1 |
UCB Ventures | 1 |
Nausicaa Ventures | 1 |
the SRIW Life Sciences | 1 |
Do and dare company
Show more
Investment focus
- Software, Biotechnology, Health Care
- Series A, Seed, Series B
- Belgium, United States, The Netherlands
Portfolio highlights
- Nobi — Fall detection for the elderly at your home or in a residential care center with the smart Nobi lamp. Nobi ensures that you can be helped quickly.
- Apideck — Integrate and monitor APIs at warp speed. Apideck is the fastest way for developers to build integrations. Connect new APIs in minutes instead of days.
- Swave Photonics — Swave develops Spatial Computing, Holography, holographic chips, and holograms in the HXR chip to create 3D augmented and virtual reality and HUD Heads Up Displays
Noshaq offers financial services to help businesses develop.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Seed, Funding Round
- Belgium, France, Germany
Portfolio highlights
- TrustUp — TrustUp is the home contractors platform, connects homeowners with verified quality home improvement.
- Veoware — More coverage, shorter revisit time. Increasing target collection frequency through modular next-gen actuator technology.
- Le Fourgon — Le Fourgon provides contained drinks for home delivery. They offer milk, water, beer, wine, fruit juice, and sodas. They allow customers to have their drinks delivered free of charge during the day.
The Qbic Fund is a multi-sector fund supporting spin-off companies of the Ghent, Brussels and Antwerp university associations and of VITO. Through its strategic partnership with the universities of Ghent, Brussels and Antwerp, and VITO, the Qbic Fund has early and privileged access to promising research projects at these partner universities. Ourinvestment approach is based on early in-depth and independent review and analysis followed by hands on involvement and support.In May 2012 the Qbic Fund held its first close and currently it has over € 30 million under management. The Qbic Fund is backed by several public and private investors and managed by Qbic Venture Partners.
Show more
Investment focus
- Biotechnology, Software, Health Care
- Seed, Funding Round, Series A
- Belgium
Portfolio highlights
- Pleevi — AI powered smart charging APIs to charge fleet more cost-efficient and cleaner on professional sites
- Weavely — Design forms in Figma - publish with Weavely. We turn your visual ideas into interactive, web-based forms.
- Confo Therapeutics — Confo Therapeutics is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. Confo Therapeutics employs its proprietary CONFO® technology to lock inherent unstable functional conformations of GPCRs as a superior starting point for drug discovery. CONFO® body-stabilized active state conformationsof these receptors disclose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention.
Oxygen for growth - LRM
Show more
Investment focus
- Information Technology, Software, Biotechnology
- Funding Round, Series A, Seed
- Belgium, United States, The Netherlands
Portfolio highlights
- Cumul.io — Create powerful dashboards in minutes. Share with your teams, or integrate in your platform. Drive growth in your business today!
- ADLC — ADLC employs drone technology to deliver logistics services, allowing businesses to implement drone-based solutions without having to manage them in-house. The company is focused on enhancing last-mile delivery in maritime and offshore environments. ADLC now conducts drone delivery services in the Port of Antwerp in collaboration with SGS, atesting and certification company, and works with companies such as BASF. Its drones have reduced delivery times and environmental effect, boosting efficiency sixfold and lowering CO2 emissions by up to 80% for petrochemical sample deliveries.
- Raw Stadia — Raw Stadia is a sports technology company that specializes in surface player interactions.
The S.R.I.W. Group is an institution at the heart of the financial market that assists entrepreneurs in creating and developing businesses in the Walloon region. It reflects the effort of Wallonian industry in facing the challenges of the creation of economic value in the 21st century.
Since its creation in 1979, the Société Régionaled’Investissement de Wallonie has continuously been expanding its abilities to adapt and anticipate as well as its flexibility in order to meet the requirements of its partners who are confronted with the evolution of the world economy. The principles of good governance, a strong business culture and shared values at the heart of the Group constitute important assets to capture the changing realities of the market and progress in a sustainable development perspective.
Show more
Investment focus
- Biotechnology, Health Care, Manufacturing
- Funding Round, Series A, Series B
- Belgium, United States, Spain
Portfolio highlights
- Univercells — We are biotech innovators, rooted in Belgium, driven by one purpose: To transform how biotech drugs are made so everyone, everywhere, can get them.
- Intressa Vascular — Intressa Vascular provides innovative solutions to address life-threatening cardiovascular conditions such as aortic dissection.
- Santero Therapeutics — Santero Therapeutics seeks to provide novel medications with fresh modes of action that combat diseases with high resistance. Santero develops antimicrobials with novel modes of action to combat the rise of antibiotic-resistant microorganisms.
Sambrinvest is an active venture capital player in the region of Charleroi - Thuin.
Show more
Investment focus
- Biotechnology, Health Care, Information Technology
- Seed, Series A, Series B
- Belgium, France, Spain
Portfolio highlights
- AdipoPharma — By harnessing the power of the Adipocyte AdipoPharma is committed to developing innovative treatment for type 2 diabetes
- AbolerIS Pharma — AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance.
- ATB Therapeutics — ATB Therapeutics is a biopharmaceutical company that provides novel therapeutic solutions and treatments for cancer patients.
Chemical, Advanced Materials, Cosmetics, Recycling, CleanTech, Plastics and Rubber Manufacturing, Nanotechnology, Biosciences
Show more
Investment focus
- Health Care, Manufacturing, Information Technology
- Funding Round, Seed, Series A
- Belgium, France, Luxembourg
Portfolio highlights
- Aloxy — Aloxy offers reliable IIot solutions tailored to the needs of the process industry. Our valve sensor provides an open and close indication of manual valves.
- Graftys — Graftys, an Aix-en-Provence, France-based early stage company focused on advanced bone biologics.
- SENSE in — SENSE in manufactures monitoring solutions based on thermomechanical sensors sensitive to deformation, pressure, temperature, humidity, and more. Their solutions evaluate in real time or periodically the expected characteristics and alert on abnormal behavior, threshold overruns, and damage.
Theodorus is the spin-off fund of Université Libre de Bruxelles that invests ininvest in early stage projects based on proprietary disruptive technologies.
Show more
Investment focus
- Health Care, Life Science, Medical
- Funding Round, Seed, Series A
- Belgium, Canada, France
Portfolio highlights
- DrugBank — DrugBank augments human intelligence to improve the world’s health. Our suite of products are powered by the world’s most complete and up-to-date pharmaceutical knowledge database. It includes everything there is to know about drugs and how they work in the body. We enable companies to improve healthcare delivery through precision medicine orclinical software applications, as well as uncover insights through data science in drug discovery. Our knowledge base can be integrated into software solutions to help achieve clinical intelligence. Companies can easily scale their usage through our API and launch faster with flexible data modules. By providing users with advanced insights and the right information at the right time, users are empowered to make better health decisions.Our extensive, structured datasets are used to discover novel drug candidates, identify drug repurposing opportunities, and build predictive machine learning models. Companies working with data science can find answers quickly and get drugs to market faster with our evidence-based drug information. Lastly, our publicly available resource, DrugBank Online, is free-to-use with limited datasets available for download for academic and non-commercial researchers. DrugBank has been cited in over 13,000 academic publications and is used by millions of researchers and health professionals globally.
- HYPNO VR — HypnoVR is a virtual reality software for anesthesia, treatment of pain, and anxiety. It was founded in 2016 and is based in Strasbourg, France.
- Cascador Health — Cascador Health bridges the gap between sources and users of healthcare data. Using curated, validated and anonymized RWD allows healthcare providers and life science industry to gain insights and provide better care.
V-Bio Ventures is an independent venture capital firm specialized in building and financing young, innovative life science companies. The fund invests throughout Europe in start-up and early-stage companies with high growth potential focusing on technologies that provide transformational improvements in the biotech, pharmaceutical and agriculturalsectors.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Seed
- Belgium, France, United Kingdom
Portfolio highlights
- ATB Therapeutics — ATB Therapeutics is a biopharmaceutical company that provides novel therapeutic solutions and treatments for cancer patients.
- Confo Therapeutics — Confo Therapeutics is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. Confo Therapeutics employs its proprietary CONFO® technology to lock inherent unstable functional conformations of GPCRs as a superior starting point for drug discovery. CONFO® body-stabilized active state conformationsof these receptors disclose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention.
- Augustine Therapeutics — Augustine, Innovative therapies for neuromuscular and neurodegenerative diseases
New Science Ventures is a venture capital firm that focuses on investments in life sciences and information technology companies. They invest in early and late stage companies taking novel scientific approaches to address significant unmet needs, while creating order-of-magnitude improvements in performances. The company also invests in companiesusing science-based innovations to address market needs in life sciences such as pharmaceuticals, biologics, medical devices, diagnostics, and IT. The team of the company expertise in strategy and corporate planning, operations and cost management, and leadership development.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series B, Series A, Series D
- United States, United Kingdom, Belgium
Portfolio highlights
- Glydways — Glydways, formerly Wayfarer is a transportation technology and clean energy company based in South San Francisco, California. It specializes in the design, manufacture, installation, and operation of affordable autonomous transportation for low, medium, and extremely high-capacity needs.
- Vuv Analytics — VUV Analytics was incorporated in Austin, TX in December 2009, as a spin-off from a semiconductor equipment company. The five founders bring with them critical and unique know-how related to the hardware, software, analysis, intellectual property, and marketing associated with VUV technologies. The team's past success in pioneering VUVreflectometry for use in the semiconductor metrology field yielded several key market wins and an extensive IP portfolio, including 32 issued patents and 12 pending patents.
- Novadip Biosciences — Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction.
Pierre Drion - CEO @ Petercam
Show more
Investment focus
- Biotechnology, Health Care, Life Science
- Series A, Series B, Funding Round
- Belgium
Portfolio highlights
- A-Mansia Biotech — A-Mansia Biotech is a developer of products based on the properties of the Akkermansia muciniphila (A. muciniphila) bacterium. The company's nutritional supplement based on a gut bacterium called Akkermansia, the population of microorganisms housed in the gastrointestinal tract. A. muciniphila is located in the mucus layer covering theintestinal epithelium, which allows the bacterium to establish a close cross-talk with the host.
- Novadip Biosciences — Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction.
- Santero Therapeutics — Santero Therapeutics seeks to provide novel medications with fresh modes of action that combat diseases with high resistance. Santero develops antimicrobials with novel modes of action to combat the rise of antibiotic-resistant microorganisms.
The Federal Holding and Investment Company (SFPI-FPIM) centrally manages the federal government’s shareholdings, cooperates with the government on specific projects and pursues its own investment policy in the interests of the Belgian economy.
Show more
Investment focus
- Health Care, Biotechnology, Medical Device
- Funding Round, Series B, Series A
- Belgium, United States, France
Portfolio highlights
- Cohabs — We create sustainable & community-driven shared homes around the world for young workers and interns. Join our community.
- Univercells — We are biotech innovators, rooted in Belgium, driven by one purpose: To transform how biotech drugs are made so everyone, everywhere, can get them.
- Tangent Works — Create predictive models in seconds for faster and better forecasting & anomaly detection with TIM InstantML.
Annie Vereecken
Show more
Investment focus
- Biotechnology, Medical, Hospital
- Seed, Series A, Funding Round
- Belgium
Portfolio highlights
- Ziphius — Ziphius Vaccines is a biopharmaceutical company dedicated to developing next-generation vaccines for the prevention of infectious diseases.
- Sensolus — Introducing our smart, industrial-grade tracking solution. With battery life of up to ten years, and no additional infrastructure needed.
- Allegro Biotech — Allegro has developed the world’s-first custom-tailored, durable, biocompatible, anisotropic, regenerative meniscus cartilage, providing immediate support while also leverage the body’s own healing potential to regenerate human cartilage (proliferation and differentiation of fibrochondrocyte cells).
Strategic research in on life sciences and biotechnology
Show more
Investment focus
- Biotechnology, Pharmaceutical, Health Care
- Series A, Series B, Funding Round
- Belgium, Brazil, Denmark
Portfolio highlights
- Protealis — Sustainable plant proteins for Europe
- Confo Therapeutics — Confo Therapeutics is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. Confo Therapeutics employs its proprietary CONFO® technology to lock inherent unstable functional conformations of GPCRs as a superior starting point for drug discovery. CONFO® body-stabilized active state conformationsof these receptors disclose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention.
- Augustine Therapeutics — Augustine, Innovative therapies for neuromuscular and neurodegenerative diseases
Luc Vauterin - Board Member @ ONTOFORCE
Show more
Investment focus
- Life Science, Data Integration, Data Visualization
- Seed, Series A
- Belgium
Portfolio highlights
- ONTOFORCE — ONTOFORCE creates and implements pioneering semantic search technology for information management. Our user-friendly data search platform DISQOVER builds uniquely intelligent links between heterogeneous data sources, allowing everybody to become a data scientist.
Fund+ is a venture capital firm that invests in companies operating in the diagnostics, therapeutics, medical devices, and life science sectors. The firm wants to create sustainable shareholders' value, contribute to the development of a leadership position in the life sciences sector, and generate a tangible, beneficial societal impact.Fund+ was established in 2015 and is based in Leuven, Belgium.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- Belgium, United States, Spain
Portfolio highlights
- Coave Therapeutics — Coave Therapeutics is active in the field of gene therapies in rare ocular and CNS (Central Nervous System) diseases.
- Confo Therapeutics — Confo Therapeutics is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. Confo Therapeutics employs its proprietary CONFO® technology to lock inherent unstable functional conformations of GPCRs as a superior starting point for drug discovery. CONFO® body-stabilized active state conformationsof these receptors disclose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention.
- Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and
Fonds Vives II (University of Louvain, UCL)
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series B, Series A, Seed
- Belgium, United States
Portfolio highlights
- Virovet — Antiviral drugs and thermostable vaccines for livestock
- Sunrise — Sunrise aims to bring simple answers to millions of people suffering from sleep disorders.We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate asin-lab sleep studies, at a fraction of the cost.Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases.Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems.
- ITeos Therapeutics — iTeos Therapeutics is pioneering the discovery and development of highly differentiated immuno-oncology therapeutics for cancer patients.
Ifoghas Investments operates as an investment firm.
Show more
Investment focus
- Medical, Health Care, Life Science
- Series A
- Belgium
Portfolio highlights
- Amyl Therapeutics — Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.
Innovation Industries is a Dutch venture capital fund investing in impactful deep tech, focusing on sustainability, scalability, and ESG-aligned companies.
Show more
Investment focus
- Semiconductor, Manufacturing, Health Care
- Funding Round, Seed, Series A
- The Netherlands, Belgium, United States
Portfolio highlights
- Carbyon — Carbyon is a Netherlands-based company that develops direct air capture (DAC) technologies. The company's fuels help to replace fossil hydrocarbons with electrical batteries or hydrogen (H2), alternative energy carriers that are used to store renewable electricity and make major changes to transportation facilities, energy grids, and gastransportation networks, filters CO2 from the air and supply it in a purified form to make kerosene for aircraft, enabling existing fossil industry to re-use and repurpose these storage and transport facilities for renewable hydrocarbons.
- PHOTON IP — PHOTON IP is a deeptech startup based in Eindhoven, the Netherlands. The company develops cutting edge technologies for advanced photonics applications.
- Battolyser Systems — Battolyser Systems aims to stimulate the development, production, and commercialization of battolyser technology and is looking for skilled and highly motivated people to join the team. The Company was founded in 2018 by dr. prof Fokko Mulder (Technical University of Delft) together with Kees Koolen (former CEO of Booking.com and former COO ofUber) and is led by CEO Mattijs Slee (previously Shell Hydrogen). The company has a unique patented technology that has the lowest production cost for green hydrogen in the market and does not require scarce materials.
Shaping new life-science ventures.
Show more
Investment focus
- Biotechnology, Therapeutics, Health Care
- Series A, Funding Round, Seed
- The Netherlands, United States, Belgium
Portfolio highlights
- Citryll — Citryll is a private pharmaceutical company that develops pharmaceutical drugs used to treat autoimmune and other human diseases. The company offers formation, function, and clearance of NETs downstream of the protein citrullination pathway catalyzed by Peptidylarginine Deiminase (PAD) enzymes that enable doctors to help in the treatment of lupus,vasculitis, pulmonary fibrosis, rheumatoid arthritis and organ damage due to sepsis.Citryll was established in 2015 and is headquartered in Oss, The Netherlands.
- Rhygaze — RhyGaze is at the forefront of developing a novel first-in-class gene therapy aimed at improving vision in patients suffering from retinal diseases.
- Kivu Bioscience — At Kivu Bioscience, we leverage advanced, next-generation proprietary ADC technologies to deliver more precise and effective cancer treatments.
Virginie Saverys is a entrepreneur.
Show more
Investment focus
- Medical, Life Science, Biotechnology
- Seed
- Belgium
Portfolio highlights
- 4Tissue — Shaping the Future of Regenerative Medicine
Griet Nuytinck is founder of Anacura.
Show more
Investment focus
- Medical, Life Science, Biotechnology
- Seed
- Belgium
Portfolio highlights
- 4Tissue — Shaping the Future of Regenerative Medicine
Vives is an interregional seed and early stage technology multi-sector fund. The new fund, initiated by UCLouvain, is a unique European inter-university fund having access to world class innovations from leading EU top universities.
Show more
Investment focus
- Health Care, Biotechnology, Medical
- Series A, Series B, Funding Round
- Belgium, France, United States
Portfolio highlights
- BOTALYS — BOTALYS uses an innovative Biomimetic Indoor Farming technology to recreate the ideal wild conditions for rare botanicals to grow in. We develop pristine & potent botanical ingredients for the Nutraceutical and Cosmetic industries.
- Sunrise — Sunrise aims to bring simple answers to millions of people suffering from sleep disorders.We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate asin-lab sleep studies, at a fraction of the cost.Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases.Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems.
- Novadip Biosciences — Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction.
6K Venture Capital operates as a venture capital firm.
Show more
Investment focus
- Medical, Software, Health Care
- Seed, Series A
- Panama, Belgium
Portfolio highlights
- Rise Of Defenders — Rise of Defenders is a very interesting Metaverse NFT game, you can use your creativity and tactical thinking to become an excellent player and receive extremely attractive rewards.
- Amyl Therapeutics — Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.
Our mission is to mature innovation and support the growth of our portfolio companies to create value for patients, society, local ecosystems, and investors.
Show more
Investment focus
- Biotechnology, Medical, Health Care
- Series A, Funding Round, Seed
- Belgium, Japan, France
Portfolio highlights
- AdipoPharma — By harnessing the power of the Adipocyte AdipoPharma is committed to developing innovative treatment for type 2 diabetes
- AbolerIS Pharma — AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance.
- Tensegrity Pharma — Tensegrity Pharma is the developer of a novel drug designed to minimize bottlenecks and provide innovative value to patients.
Capricorn Partners is a unique independent manager of venture capital, growth capital and quoted equity funds
Show more
Investment focus
- Biotechnology, Health Care, Software
- Funding Round, Series B, Series A
- Belgium, United States, The Netherlands
Portfolio highlights
- InsectSense — MIMICKING HOW INSECTS SENSE | Biomimetic technology based on the sensing mechanism of insects. A deeptech platform that applies synthetic biology, microfluidics and is powered by machine learning.
- Thryve — Thryve’s SDK brings everything you need to access fragmented wearable, medical devices, and health data silos with a single integration. We unify your users’ data from smartwatches, blood glucose meters, and many other sources that unlock a continuous stream of harmonized health information for your care. We support popular data sources like AppleHealth, Google Fit, Huawei Health, Samsung Health, and many more.
- Minze Health — Minze Health is a health tech start-up that builds creative digital health solutions for urology, pelvic health, and (in)continence care.
Evren Ucok is a co-founder and investor at Peak Games, an interactive social game development platform.
He is also a partner at Earlybird Venture Capital, an investment fund-based in Europe that focuses on emerging companies; Trendyol.com, a fashion e-commerce site; and Oliver Wyman.
Show more
Investment focus
- Medical, Health Care, Life Science
- Series A
- Turkey, Belgium
Portfolio highlights
- idemama — Idemama is an online platform that provides its users with web and graphic design services. It is based in Istanbul, Turkey.
- Amyl Therapeutics — Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.
Epimède SA
Show more
Investment focus
- Biotechnology, Medical, Health Care
- Series B, Series C, Series D
- Belgium, The Netherlands
Portfolio highlights
- Imcyse — Imcyse is a clinical stage biopharmaceutical company pioneering the development of a new class of active specific immunotherapies for the treatment of severe chronic autoimmune diseases. The company’s unique technology platform allows it to locally target immune cells involved in the destruction of the diseased organ. This platform is based on theadministration of Imotopes™, which are specifically modified peptides, allowing for the generation of cytolytic CD4 T-cells, that specifically eliminate antigen-presenting cells and autoantigen specific lymphocytes. Imcyse’s approach, sustained over time, helps to prevent and treat diseases with no current therapeutic alternative and to potentially cure patients without impairing immune defense. The company has established proof of concept in several indications and has completed its first clinical trial in type 1 diabetes with promising results. Beyond type 1 diabetes, Imcyse is developing a pipeline of Imotopes™ for the treatment of several autoimmune diseases.
- Ncardia — At Ncardia, we believe that human stem cell technology will help get better therapies to patients faster.
- Endo Tools Therapeutics — Endo Tools Therapeutics is dedicated to the development of innovative devices that provide therapeutic interventions for gastric conditions
Qbic is the result of a lot of thinking, debating and sketching of what a city hotel could be; one that breaks the rules and makes people smile.An astonishing level of change has swept through the world over the last few years. But the hotel experience is no different than it’s ever been: stuffy, over-priced and lacking soul. They’re here tochange all that. they’re curious, imaginative and friendly, and they think there are lots of people just like us seeking a hotel with personality in the middle of the city.They believe in something better than what’s currently out there. A place that celebrates life rather than sucks life out of it. A hotel that’s built on creativity and a belief that you don’t have to accept the conventional. Somewhere that sends you away with fun stories and ideas, and is easy on your pocket.
Show more
Investment focus
- Health Care, Biotechnology, AgTech
- Seed, Series B, Funding Round
- Belgium
Portfolio highlights
- moveUP — Ontvang medische zorg op afstand voor en na uw operatie. moveUP is gespecialiseerd in de begeleiding van knie- en heupoperaties.
- Axithra — Axithra provides therapeutic medication monitoring and measures beta-lactam antibiotic concentrations in blood.
- Cascador Health — Cascador Health bridges the gap between sources and users of healthcare data. Using curated, validated and anonymized RWD allows healthcare providers and life science industry to gain insights and provide better care.
Korys is the name chosen by the Colruyt family for their investment structure. The name Korys is derived from the Latin word for hazelnut tree – Corylus - which is at the origin of the Colruyt name.Their multi-disciplinary approach enables us to create a well-balanced, diversified portfolio of listed stocks and bonds, private equity funds, anddirect participations in small and medium-sized companies. Through their investments, they aim to make a positive impact on people and the planet, while generating attractive returns. A “three P” approach (People, Planet, Profit) forms the cornerstone of their investment strategy. They invest for the long term, as they realize that it takes time to achieve the sustainable impact they are aiming for. They focus their investments in sectors in which they have built substantial expertise as a team: Cleantech, consumer goods & retail and life sciences.
Show more
Investment focus
- Biotechnology, Information Technology, Renewable Energy
- Funding Round, Series A, Series B
- Belgium, The Netherlands, Germany
Portfolio highlights
- Greenely — Greenely is the electricity company that optimizes your electricity use using smart technology in an app. We help you take control of your consumption.
- OroraTech — OroraTech provides global real-time information services. The first target market is early detection and monitoring of wildfires, extended by a proprietary constellation of thermal imaging nanosatellites equipped with in-space AI image processing. At the beginning of 2020, OroraTech launched an MVP called Wildfire Service (WFS) that enables quickdetection and monitoring of wildfires on a global scale. The combination of existing thermal-infrared satellite data with external data layers, such as fuel, wind, and risk maps results in an automatic generation of fire alerts and the display of current fire perimeters for users. The MVP was launched in early 2020 and has gained increasing traction with governmental and large corporate customers all over the world.
- PanTera — PanTera wants to bring a new hope to cancer patients by enabling the widespread use of radiopharmaceuticals for personalised treatment of tumors
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases.
Show more
Investment focus
- Biotechnology, Therapeutics, Health Care
- Series A, Series C, Seed
- United States, Denmark, France
Portfolio highlights
- ElevateBio — We provide the tools, time, and environment to innovate and accelerate development of life-saving Cell and gene therapies.
- Tanai Therapeutics — Tanai Therapeutics develops novel therapeutics for people living with obesity and obesity-related complications.
- Eikonizo Therapeutics — Eikonizo is developing life-changing treatments by producing brain-penetrant small compounds and utilizing in vivo target engagement approaches to speed therapeutic discovery.
The European Investment Bank (EIB) offers lending, borrowing, and treasury services primarily within the European Union. It provides project loans for public and private sectors, loans to banks and intermediaries, structured finance products, guarantees, and securitization instruments for debts. Additionally, EIB offers equity and fund investmentproducts, including infrastructure and environmental funds, as well as venture capital funds. EIB also supports microfinance and risk-sharing finance for research and innovation and provides technical expertise for sustainable energy projects. Its services include infrastructure advisory, urban development support, guarantees for transport infrastructure, and funding for public-private partnerships and small- to medium-sized enterprises. The bank serves various sectors, including transportation, energy, health, education, and agriculture.
Show more
Investment focus
- Biotechnology, Health Care, Energy
- Debt Financing, Post-IPO Debt, Funding Round
- Germany, France, The Netherlands
Portfolio highlights
- Amadix — Amadix develops and commercializes breakthrough discoveries in cancer diagnosis with a clear commercial rationale, addressing unmet medical needs in oncology. After analytical validation and demonstration of clinical validity and utility through international multicentre studies, the products will be commercialized worldwide.The most advancedproduct developed by Amadix is Colofast, an innovative non-invasive screening signature for colorectal cancer (CRC) and advanced adenoma diagnosis in blood designed to solve a significant health priority: the high mortality rate due to colon cancer worldwide (around half of the diagnosed patients).Amadix team consist of industry veterans with robust expertise in the Oncology Diagnostic area. They are a top level management team with international experience in cancer diagnostics, the pharmaceutical industry, the biotechnology sector and intellectual property. Amadix also has independent board members with international profiles and many years of experience in oncology and diagnostics, who advise the management team on strategy, commercialization and business development in Europe and the US.
- Greenlight Biosciences — Next Generation Crop Protection
- Azienda Comprensoriale Acquedottistica — ACA Spa is an integrated water service company.
invest.bw is a venture capital firm.
Show more
Investment focus
- Health Care, Neuroscience
- Seed
- United States
Portfolio highlights
- BiocSol — BiocSol focus on sustainable microbial-based crop protection.
- VOCSense — VOCSens spin-off is developing a new concept of an environmental camera, EnviCam®, allowing you to see the invisible, those chemical and biochemical molecules that surround us. The company has developed a manufacturing process, CMOSEnvi™, fully compatible with the CMOS technology found in everyday electronic chips.
- neuroClues — An easy-to-use eye-tracking environment to help practitioners instantaneously quantify their clinical exam
Seventure Partners is a French venture capital firm targeting in Tech/Digital and Life Sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with € 1 billion undermanagement as of December 31, 2023. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.The different funds/verticals on which Seventure Partners are focusing on today:
- Life Sciences : Biotech, Healthcare, Nutrition
- Tech/Digital : B2B SaaS, Fintech, Retailtech, Cybersecurity
- Sports & Wellbeing
- Blue Economy
Show more
Investment focus
- Biotechnology, Health Care, Software
- Series A, Funding Round, Series B
- France, United States, Germany
Portfolio highlights
- FIRE1 — FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.
- Karmen — Karmen offers revenue-based financial solutions such as venture capital and loans to accelerate business growth for SaaS companies.
- Anybuddy — Anybuddy is a sport booking marketplace, leader in racket sport in France
Venture Capital firm based in London. We help enable business funding though capital investment. In turn, that funds and drives business growth as exceptional speed. Visit our site to find out how our proven model of business investment can help your start up.
Show more
Investment focus
- Medical, Health Care, Life Science
- Series A
- Belgium
Portfolio highlights
- Amyl Therapeutics — Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.
Mérieux Développement is specialized in Growth and Venture capital transactions in the healthcare and nutrition sectors. We support companies with products or services offering true differentiation and capacity to create substantial value over the long term. Our investment team, based in Europe and North America, brings its expertise andinternational network to help entrepreneurs disrupt and grasp substantial market opportunities. Mérieux Développement is an affiliate of Institut Mérieux, which employs approximately 17,000 employees worldwide, with consolidated revenues exceeding 2.5 billion Euros in 2017.
Show more
Investment focus
- Health Care, Biotechnology, Medical Device
- Funding Round, Series C, Series B
- France, United States, Belgium
Portfolio highlights
- SeqOne Genomics — Healthcare is undergoing a revolution, known as genomic medicine, that uses the patient’s genomic information to optimise treatment. This trend is accelerating thanks to the arrival of New Generation Sequencing (NGS) techniques that have reduced the cost of decoding genomic material while increasing the amount useful data obtained. However, NGShas had only limited impact on mainstream healthcare due to the difficulties in analyzing more and richer genomic data. SeqOne’s mission is to provide tools that enable the healthcare industry to analyse NGS genomic data better and more cost-effectively to provide universal access to genomic medicine.
- TISSIUM — TISSIUM is creating the future of tissue reconstruction. Learn more about our novel solutions based on our proprietary platform of biomorphic programmable polymers.
- Amyl Therapeutics — Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.
OBI SA
Show more
Investment focus
- Life Science, Biotechnology, Health Diagnostics
- Funding Round
- Belgium
Portfolio highlights
- Diagenode — Diagenode is an international life sciences company that develops and commercializes innovative instruments and reagents systems for life science research and molecular diagnostics. Founded in 2003 in Liege (Belgium), Diagenode is a global company, with headquarters in Liege, Belgium and Sparta, NJ, USA. Diagenode also has a local sales office inthe United Kingdom to better serve this specific country.Diagenode's customers include leading epigenetics researchers, academic institutions, high-profile genome centers and core labs, life sciences tools companies, molecular diagnostics players, and pharmaceutical and biotechnology companies.Epigenetics Division
VIVES is a seed capital fund initiated by UCLouvain which invests in companies developing disruptive innovations with a positive societal impact.
Show more
Investment focus
- Biotechnology, Therapeutics, Farming
- Seed, Series A
- Belgium, France
Portfolio highlights
- BiocSol — BiocSol focus on sustainable microbial-based crop protection.
- Generare — Harness the ingenuity of nature to transform small molecule discovery
- ATB Therapeutics — ATB Therapeutics is a biopharmaceutical company that provides novel therapeutic solutions and treatments for cancer patients.
Annemie Van de Casteele is a former member of the Belgian Parliament.
Show more
Investment focus
- Medical, Life Science, Biotechnology
- Seed
- Belgium
Portfolio highlights
- 4Tissue — Shaping the Future of Regenerative Medicine
Kenneth Buckfire is the Chief Executive Officer at Miller Buckfire.
Show more
Investment focus
- Medical, Health Care, Life Science
- Series A
- Belgium
Portfolio highlights
- Amyl Therapeutics — Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.
Opdorp Finance BVBA
Show more
Investment focus
- Life Science, Data Integration, Data Visualization
- Series A
- Belgium
Portfolio highlights
- ONTOFORCE — ONTOFORCE creates and implements pioneering semantic search technology for information management. Our user-friendly data search platform DISQOVER builds uniquely intelligent links between heterogeneous data sources, allowing everybody to become a data scientist.
W.IN.G by Digital Wallonia invests in SAAS, advanced tech and deep tech startups (AI, drones, medtech, IOT,...). W.IN.G brings smart money by helping startups by bi-weekly interactions and providing an operating teams (seasonal entrepreneurs being hands-on with the portfolio).
Show more
Investment focus
- Software, Health Care, Internet
- Seed, Convertible Note, Series A
- Belgium
Portfolio highlights
- IONNYK — IONNYK is a new medium of art photography, containing millions of tiny ink capsules.
- MYOCENE — Myocene is a Liège-based sports technology company which creates unique and innovative devices for measuring muscle fatigue and performance.
- Soil Capital Belgium — Discover Europe's first certified, multi-national carbon farming programme that rewards regenerative agriculture.
UCB Ventures is a €150 million strategic corporate venture fund
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Seed
- United States, Belgium, Spain
Portfolio highlights
- ViaNautis — Precision Solutions
- Neurona Therapeutics — Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs.
- Switch Therapeutics — Switch Therapeutics is a biotech company dedicated to revolutionizing RNA interference (RNAi) therapies with conditionally activated siRNAs (CASi).
A multi-industry early stage venture capital fund Nausicaa Ventures is an early stage investment fund organisation focused on investment rounds between EUR 1 and 4 million. Nausicaa Ventures was created in 2009 by bringing together 35 private investors and selected institutional investors, such as the European Investment Fund or ING Bank, under the management of ...
Show more
Investment focus
- Software, CRM, Big Data
- Series B, Funding Round
- Belgium
Portfolio highlights
- NGDATA — NGDATA is the consumer intelligence management solutions company that empowers enterprises seeking greater customer lifetime value to drive continuous, actionable insights to enable sales and increase customer loyalty.The company does this through its unique combination of Big Data management and machine learning technologies in a singleintegrated solution.Recently named one of Bank Systems and Technology Magazine’s “Top 7 Big Data Players to Watch,” NGDATA is headquartered in Ghent, Belgium with offices in New York City and San Francisco. The company provides solutions to data-driven sectors such as financial services, retail and media/publishing.
- Ovizio — Optimize your process, control your CPPs & monitor quality while reducing hands-on time and risk of contamination.
the SRIW Life Sciences
Show more
Investment focus
- Biotechnology, Medical, Biopharma
- Series A, Series B
- Belgium
Portfolio highlights
- A-Mansia Biotech — A-Mansia Biotech is a developer of products based on the properties of the Akkermansia muciniphila (A. muciniphila) bacterium. The company's nutritional supplement based on a gut bacterium called Akkermansia, the population of microorganisms housed in the gastrointestinal tract. A. muciniphila is located in the mucus layer covering theintestinal epithelium, which allows the bacterium to establish a close cross-talk with the host.
- Novadip Biosciences — Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction.
Investors by industry
Biotech
Energy
Health Care
Hardware
Gaming
Google
Artificial intelligence
Climate
Proptech
Community
FinTech
Consumer
Marketplace
Impact
EdTech
Sustainability
Venture Capital
Retail
Clean Energy
Finance
Education
Organic Food
Big Data
Web3
Food and Beverage
Financial Services
Payments
B2B
Real Estate
Publishing
Video Games
Beauty
Infrastructure
Photography
Medical
Social Network
Wellness
Music
Franchise
Mobile
Internet
Legal
Android
eSports
Construction
Sports
Enterprise Software
Social Media
Email
Art
Digital Media
Manufacturing
Local
Cannabis
Biotechnology
Recruiting
Fitness
Hospitality
Platforms
Mobile Advertising
Travel
Automotive
Wine And Spirits
Medical Device
Crowdfunding
Social
CleanTech
Transportation
Mobile Apps
InsurTech
Enterprise
LGBT
Oil and Gas
Fashion
Theatre
Life Science
Film
Non Profit
Renewable Energy
SaaS
Sporting Goods
Restaurants
Social Impact
Software
Celebrity
Cryptocurrency
Agriculture (agtech)
Media (entertainment)
Facebook
Blockchain
Investors by country
India
United Kingdom
Germany
United States
South Korea
Canada
Ireland
Australia
New Zealand
Oceania
LATAM
Africa
Asia
Japan
Saudi Arabia
China
Singapore
Spain
Vietnam
Armenia
South Africa
Middle East
Sri Lanka
Brazil
Indonesia
Europe
Qatar
Liechtenstein
Faroe Islands
Barbados
Denmark
Chile
Ecuador
Ethiopia
Estonia
Hong Kong
France
Gibraltar
Costa Rica
Greece
Finland
Croatia
Egypt
Georgia
Algeria
Ghana
Bulgaria
Bermuda
Hungary
Czech Republic
Bahrain
Belize
Belgium
Belarus
Serbia
Ukraine
Uganda
Uzbekistan
Thailand
Portugal
Senegal
Sierra Leone
Venezuela
Russian Federation
Tajikistan
Rwanda
Zimbabwe
Zambia
Seychelles
Taiwan
Sweden
El Salvador
Tunisia
San Marino
Poland
Turkey
Puerto Rico
Uruguay
Slovenia
Togo
Tanzania
Dominican Republic
Iraq
Nigeria
Bahamas
Namibia
Azerbaijan
Iceland
United Arab Emirates
Jamaica
Honduras
Isle of Man
Bolivia
Luxembourg
Pakistan
Albania
Bangladesh
Grenada
Romania
Jordan
Argentina
Morocco
Liberia
Lebanon
Lithuania
Kuwait
Philippines
Mexico
Norway
Jersey
Mauritius
Israel
Malaysia
Peru
Malta
Myanmar
Italy
Kazakhstan
Kenya
Cayman Islands
Cambodia
Mali
Nicaragua
Panama
Latvia
Oman
Cyprus
Cameroon
Austria
Switzerland
Marshall Islands
Colombia
Guatemala
Investors in Belgium by industry
Restaurants
InsurTech
Financial Services
Big Data
Cryptocurrency
Finance
Food and Beverage
Medical
Wellness
Medical Device
Consumer
Internet
Social Network
Manufacturing
Digital Media
Mobile
Blockchain
Non Profit
Legal
Construction
Software
Sports
Payments
Enterprise Software
Fitness
Hospitality
Automotive
Recruiting
Mobile Advertising
Platforms
Biotechnology
Enterprise
Health Care
Biotech
EdTech
Climate
Energy
Sustainability
Impact
Proptech
SaaS
Marketplace
Artificial intelligence
Community
Real Estate
Mobile Apps
Infrastructure
Fashion
Web3
B2B
Life Science
Photography
Publishing
Education
Clean Energy
Renewable Energy
Music
Transportation
Retail
FinTech
Social Media
Gaming
Media (entertainment)
CleanTech
Agriculture (agtech)
Hardware